Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China · Delayed Price · Currency is CNY 21.86
-0.45 (-2.02%)
Oct 30, 2026, 3:04 PM CST
Hybio Pharmaceutical Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 205.63 | 100.72 | 94.87 | 344.01 | 106.26 | 138.92 |
Trading Asset Securities | - | 1.23 | 1.11 | - | 160.57 | 477.68 |
Cash & Short-Term Investments | 205.63 | 101.95 | 95.97 | 344.01 | 266.83 | 616.6 |
Cash Growth | 46.43% | 6.23% | -72.10% | 28.92% | -56.73% | 36.52% |
Accounts Receivable | 347.01 | 131.43 | 99.87 | 145.42 | 318.07 | 282.64 |
Other Receivables | 9.88 | 7.24 | 11.15 | 22.44 | 11.88 | 54.39 |
Receivables | 356.89 | 138.67 | 111.02 | 167.87 | 329.95 | 337.03 |
Inventory | 498.15 | 261.38 | 238.63 | 152.59 | 189.96 | 157.14 |
Prepaid Expenses | - | 8.84 | 10.29 | 2.56 | 0.19 | - |
Other Current Assets | 51.75 | 12.72 | 7.14 | 16.61 | 25.39 | 44.31 |
Total Current Assets | 1,112 | 523.56 | 463.05 | 683.64 | 812.32 | 1,155 |
Property, Plant & Equipment | 1,863 | 1,745 | 1,674 | 1,734 | 1,942 | 1,993 |
Long-Term Investments | 15.85 | 81.19 | 89.11 | 105.85 | 131.11 | 139.74 |
Goodwill | - | - | - | - | - | 0.19 |
Other Intangible Assets | 316.84 | 262.85 | 293.41 | 222.5 | 265.05 | 263.56 |
Long-Term Deferred Tax Assets | 40.39 | 41.88 | 43.76 | 39.55 | 38.01 | 34.07 |
Long-Term Deferred Charges | 133.43 | 233.07 | 175.99 | 217.81 | 250.41 | 228.02 |
Other Long-Term Assets | 463.68 | 266.29 | 268.53 | 273.73 | 172.5 | 93.2 |
Total Assets | 3,946 | 3,154 | 3,008 | 3,277 | 3,611 | 3,906 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Accounts Payable | 409.94 | 261.97 | 218.26 | 108.5 | 129.05 | 90.73 |
Accrued Expenses | 30.23 | 68.59 | 78.5 | 100.92 | 49.16 | 72.78 |
Short-Term Debt | 939.57 | 1,033 | 638.99 | 634.21 | 320.92 | 338.23 |
Current Portion of Long-Term Debt | - | 249.16 | 293.53 | 453.18 | 456.11 | 63.05 |
Current Portion of Leases | - | 0.82 | 0.82 | 0.21 | 2.88 | 11.06 |
Current Income Taxes Payable | - | 7.97 | 6.72 | 2.84 | - | 0.32 |
Current Unearned Revenue | 204.82 | 108.21 | 130.55 | 55.33 | 62.69 | 48.79 |
Other Current Liabilities | 209.05 | 51.68 | 57.17 | 68.26 | 127.14 | 118.86 |
Total Current Liabilities | 1,794 | 1,782 | 1,425 | 1,423 | 1,148 | 743.82 |
Long-Term Debt | 933.61 | 626.9 | 864.58 | 942.05 | 1,026 | 1,377 |
Long-Term Unearned Revenue | 112.65 | 97.69 | 106.91 | 101.19 | 118.62 | 124.73 |
Long-Term Deferred Tax Liabilities | 18.15 | 15.41 | 8.84 | 5.01 | 4.2 | 0.81 |
Other Long-Term Liabilities | 2.32 | 2.32 | 6.29 | 22.29 | 17.06 | 12.3 |
Total Liabilities | 2,860 | 2,524 | 2,411 | 2,494 | 2,314 | 2,258 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Common Stock | 883.24 | 883.24 | 883.24 | 883.24 | 916.93 | 916.93 |
Additional Paid-In Capital | 1,469 | 1,448 | 1,448 | 1,463 | 1,748 | 1,700 |
Retained Earnings | -1,320 | -1,757 | -1,794 | -1,627 | -1,113 | -740 |
Treasury Stock | - | - | - | - | -318.66 | -318.66 |
Comprehensive Income & Other | 39.24 | 39.97 | 41.22 | 39.27 | 37.5 | 26.51 |
Total Common Equity | 1,071 | 613.95 | 578.63 | 758.8 | 1,271 | 1,585 |
Minority Interest | 14.52 | 15.98 | 18.42 | 24.41 | 26.3 | 63.31 |
Shareholders' Equity | 1,086 | 629.93 | 597.05 | 783.21 | 1,297 | 1,648 |
Total Liabilities & Equity | 3,946 | 3,154 | 3,008 | 3,277 | 3,611 | 3,906 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Total Debt | 1,873 | 1,910 | 1,798 | 2,030 | 1,806 | 1,789 |
Net Cash (Debt) | -1,668 | -1,808 | -1,702 | -1,686 | -1,540 | -1,173 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -1.83 | -1.98 | -1.96 | -1.90 | -1.74 | -1.14 |
Filing Date Shares Outstanding | 919.98 | 883.24 | 883.24 | 883.24 | 883.24 | 883.24 |
Total Common Shares Outstanding | 919.98 | 883.24 | 883.24 | 883.24 | 883.24 | 883.24 |
Working Capital | -681.19 | -1,258 | -961.51 | -739.8 | -335.63 | 411.26 |
Book Value Per Share | 1.16 | 0.70 | 0.66 | 0.86 | 1.44 | 1.79 |
Tangible Book Value | 754.41 | 351.1 | 285.21 | 536.31 | 1,006 | 1,321 |
Tangible Book Value Per Share | 0.82 | 0.40 | 0.32 | 0.61 | 1.14 | 1.50 |
Buildings | - | - | 173.42 | 1,560 | 1,537 | 1,058 |
Machinery | - | 1,138 | 896.3 | 832.92 | 774.95 | 769.85 |
Construction In Progress | - | 136.08 | 37.11 | 67.32 | 153.99 | 699.74 |